| 前收盘价格 | 2.98 |
| 收盘价格 | 3.02 |
| 成交量 | 310,657 |
| 平均成交量 (3个月) | 651,556 |
| 市值 | 112,039,208 |
| 预期市盈率 (P/E Forward) | 5.13 |
| 价格/销量 (P/S) | 0.750 |
| 52周波幅 | |
| 利润日期 | 16 Mar 2026 |
| 营业毛利率 | -191.50% |
| 营业利益率 (TTM) | -55.31% |
| 稀释每股收益 (EPS TTM) | 29.61 |
| 季度收入增长率 (YOY) | -14.10% |
| 流动比率 (MRQ) | 0.110 |
| 营业现金流 (OCF TTM) | -145.74 M |
| 杠杆自由现金流 (LFCF TTM) | -114.08 M |
| 资产报酬率 (ROA TTM) | -28.70% |
市场趋势
| 短期 | 中期 | ||
| 行业 | Biotechnology (US) | 看涨 | 混合的 |
| Biotechnology (全球的) | 看涨 | 混合的 | |
| 股票 | Agenus Inc. | 混合的 | 看涨 |
AIStockmoo 评分
| 分析师共识 | 2.0 |
| 内部交易活动 | NA |
| 价格波动 | -2.0 |
| 技术平均移动指标 | 0.0 |
| 技术振荡指标 | 0.5 |
| 平均 | 0.13 |
|
Agenus Inc is an American clinical-stage company with a pipeline of therapies designed to activate the body’s immune system to fight cancer and infections, including immune-modulatory antibodies, adoptive cell therapies through its subsidiary MiNK Therapeutics Inc. and vaccine adjuvants through its subsidiary SaponiQx Inc. This robust product pipeline is supported by company's in-house capabilities, including current good manufacturing practice (cGMP) manufacturing and a clinical operations platform. The company's antibody candidates are botensilimab (a proprietary next-generation Fc-engineered CTLA-4 antibody, also known as AGEN1811) and balstilimab (a PD-1 antibody). |
|
| 部门 | Healthcare |
| 行业 | Biotechnology |
| 投资方式 | Small Value |
| 内部持股比例 | 1.93% |
| 机构持股比例 | 33.95% |
所有权
| 姓名 | 日期 | 持有股份 |
|---|---|---|
| Panagora Asset Management Inc | 31 Dec 2025 | 163,148 |
该时间范围内无数据。
支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。
投资组合